Lenacapavir 464 Mg Solution For Injection Gilead
PDF Leaflet Revision Date: 21 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Pre-exposure prophylaxis (PrEP) for HIV-1 prevention.
Dosage (summary)
Initiation: 927 mg subcutaneous + 600 mg oral on Day 1, 600 mg oral on Day 2; Maintenance: 927 mg subcutaneous every 6 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Considered safe during pregnancy; low levels in breast milk, no adverse effects in infants.
Key Drug Interactions
- Strong inducers of CYP3A
- St. John's wort
- Carbamazepine
- Phenytoin
Contraindications
- Hypersensitivity
- Unknown HIV-1 status
Common side effects
- Injection site reactions
- Pain
- Swelling
- Induration
Counselling Points
- Adhere to dosing schedule
- Confirm HIV-1 negative status before initiation
- Use safer sex practices
Serious warnings
- Risk of HIV-1 acquisition if not adherent to dosing
- Injection site necrosis with improper administration
Important Disclaimer
The Lenacapavir 464 Mg Solution For Injection Gilead professional information leaflet below is the property of Gilead Sciences South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
